Open AccessInhibition of breast cancer cells by targeting E2F-1 gene and expressing IL15 oncolytic adenovirus
Author(s) -
Yan Yang,
Huibin Xu,
Jiandong Wang,
Xin Wu,
Wen Wang,
Yan Liang,
Lingdi Wang,
Fengyuan Liu,
Xiaohui Du
Publication year - 2019
Publication title -
bioscience reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.938
H-Index - 77
eISSN - 1573-4935
pISSN - 0144-8463
DOI - 10.1042/bsr20190384
Subject(s) - oncolytic virus , oncolytic adenovirus , cancer research , genetic enhancement , breast cancer , adenoviridae , e2f , in vivo , cancer , virus , biology , cancer cell , virotherapy , virology , gene , cell cycle , genetics
The wide application of oncolytic adenovirus presents a novel therapeutic strategy for breast cancer gene therapy. Application of adenovirus alone achieves little curative effects on breast cancer. In addition, it is worth exploring the synergistic anti-tumor effect by inserting immunomodulatory factor in oncolytic adenovirus genome. By taking the advantage of the highly proliferative property of breast cancer, a novel recombinant adenovirus which could selectively kill tumor cells is established under an E2F-1 promoter. Also by carrying human Interleukin-15 (IL-15) gene, the oncolytic adenovirus exhibits an immunomodulatory effect. The present study proved that the novel oncolytic virus (SG400-E2F/IL-15) exhibits an enhanced anti-tumor activity both in vitro and in vivo , representing an experimental basis for breast cancer "virus-gene" therapy.